Inhibikase Therapeutics (IKT) Misses Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics (NASDAQ: IKT) reported Q2 EPS of ($0.11).
For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toro Company (TTC) Tops Q3 EPS by 3c; offers guidance
- KeyBanc on Microsoft (MSFT): 'A Cleaner Azure Disclosure'
- John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
